Table 1. Patient demographics and disease characteristics at baseline.
| Characteristic | No. | % |
|---|---|---|
| Age, years | ||
| Median (Range) | 56 (34 - 74) | |
| Sex | ||
| Male | 42 | 70.0 |
| Female | 18 | 30.0 |
| ECOG performance status | ||
| 0 | 31 | 51.7 |
| 1 | 29 | 48.3 |
| Diabetes | ||
| Yes | 12 | 20.0 |
| No | 48 | 80.0 |
| Tumor grade differentiation | ||
| Well/Moderate | 43 | 71.7 |
| Moderate-poor/Poor | 17 | 28.3 |
| Stage | ||
| Locally advanced | 5 | 8.3 |
| Metastatic | 55 | 91.7 |
| Location of primary tumor | ||
| Head/neck of pancreas | 17 | 28.3 |
| Body/tail of pancreas | 43 | 71.7 |
| Prior surgical resection * | 3 | 5.0 |
| Site of metastatic disease | ||
| Abdomen/peritoneal | 9 | 15.0 |
| Liver | 47 | 78.3 |
| Lung | 8 | 13.3 |
| Others | 3 | 5.0 |
| Liver only | 24 | 40.0 |
| No. of metastatic disease | ||
| 0 | 5 | 8.3 |
| 1 | 30 | 50.0 |
| 2 | 15 | 25.0 |
| ≥ 3 | 10 | 16.7 |
| CA19-9 baseline levels, No. | ||
| Normal | 8 | 13.3 |
| Elevated | 52 | 86.7 |
| CA19-9 baseline, U/mL # | ||
| Median (Range) | 2189 (1 - >20,000) |
Abbreviation: ECOG, Eastern Cooperative Oncology Group.
* Three patients had history of prior surgical resection including one treated with gemcitabine alone as adjuvant therapy more than six months before enrollment.
# Normal CA19-9 levels are ≤ 35 U/mL in our hospital.